RxDoctor Payments Data

Gary Vandeventer, MD

Gastroenterology · Santa Barbara, CANPI 1285628933

Payments from drug & device makers

$2,202in general payments, 2019–2025

Across 65 payments — averaging $33.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$523
  • Pfizer$299
  • Madrigal Pharmaceuticals$297
  • Ferring Pharmaceuticals Inc.$263
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$253
  • W. L. Gore & Associates, Inc.$173
  • plus $394 from 7 others

What the payments were for

  • Food & beverage$2,08995%
  • Education$1135%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,202 in reported general payments places this provider in the 50th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$162,201
Medicare patients
491
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Mesalamine28$34,256
CreonLipase/Protease/Amylase12$11,854
ClenpiqSod Picosulf/Mag Ox/Citric Ac66$11,403
Budesonide EcBudesonide34$7,955
MotegrityPrucalopride Succinate12$6,409
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates69$4,498
Dexlansoprazole DrDexlansoprazole14$3,641
Balsalazide Disodium16$3,582
Budesonide DrBudesonide11$1,535
Pantoprazole Sodium61$1,162
Omeprazole77$810
Famotidine59$676
Tenofovir Disoproxil Fumarate12$310
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl20$217
Metoclopramide Hcl149$176

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$523$11,85412 claims
Ferring Pharmaceuticals Inc.Clenpiq$263$11,40366 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$41$6,40912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →